Identifying effective strategies to promote high-value, evidence-based prescribing is critical in oncology, where spending is projected to surpass $150 billion in 2020, driven in large part by cancer drugs.1 By intentionally modifying the way choices are framed, behavioral nudges can lead to desirable changes in prescribing while preserving clinician choice, and have been used effectively in primary care settings.2 It is unknown whether nudges can also influence specialty drug prescribing, where financial incentives often favor more expensive therapies.3
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Takvorian SU, Ladage VP, Wileyto EP, et al. Association of Behavioral Nudges With High-Value Evidence-Based Prescribing in Oncology. JAMA Oncol. Published online April 30, 2020. doi:10.1001/jamaoncol.2020.0746
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: